November 06, 2018
Rose
Potential sell-off plans include Insys' Subsys, a mouth-spray version of the fentanyl painkiller, and formulations of buprenorphine. In other pharma news, the FDA continues to find quality control problems at Akorn manufacturing plants.
from Kaiser Health News https://ift.tt/2zvO9Bz
November 06, 2018
Rose
Health News, Kaiser Health News
No comments
Related Posts:
New Weight Loss Treatment Is Marked by Heavy Marketing and Modest Results- Tribes Show Little Interest in Offering Abortions on Reservations Despite Speculation They Could
- Senate Deal Raises Hopes for a Reduction in Gun Suicides
- Pesa el legado de Trump, mientras Colorado busca zanjar la brecha del seguro de salud hispano
- Trump’s Legacy Looms Large as Colorado Aims to Close the Hispanic Insurance Gap
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment